Pharmaceuticals

ACE Inhibitors Market Outlook 2025–2029: Emerging Opportunities and Key Drivers

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the ace inhibitors market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The ACE Inhibitors Market And What Value Is Projected For 2029?

The market for ACE inhibitors has experienced consistent expansion over recent years. This market is projected to expand from $7.15 billion in 2024 to $7.41 billion in 2025, achieving a compound annual growth rate (CAGR) of 3.6%. Historically, this expansion has been driven by factors such as the heightened incidence of cardiovascular disease, a growing elderly demographic, proven clinical effectiveness and safety profiles, the widespread prevalence of diabetes, and supportive regulatory endorsement and guidelines.

The ACE inhibitors market size is anticipated to undergo substantial expansion in the coming years, projected to reach $9.42 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 6.2%. This expected growth throughout the forecast period stems from the escalating global prevalence of cardiovascular diseases, the expansion of hypertension treatment guidelines, advancements in combination therapies, an increased focus on heart failure management, and rising awareness alongside improved healthcare access. Significant trends observed during this period include an emphasis on kidney protection, a growing preference for renin-angiotensin system inhibitors, generic competition and associated pricing pressures, the implementation of patient-centric approaches in healthcare, and continuous regulatory updates and safety considerations.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What Factors Are Boosting The ACE Inhibitors Market?

The rising incidence of hypertension disorders is anticipated to propel the expansion of the ACE inhibitors market moving forward. Hypertension, commonly known as high blood pressure, is a medical state marked by elevated pressure inside the blood vessels. ACE inhibitors, or angiotensin-converting enzyme inhibitors, represent a class of medications used to manage and treat hypertension. These drugs function by relaxing the blood vessels, which leads to a decrease in blood pressure and improved blood flow. For instance, in March 2023, the World Health Organization, a specialized United Nations agency based in Switzerland, reported that approximately 1.28 billion adults aged 30 to 79 were affected by hypertension globally, with the majority (two-thirds) residing in low- and middle-income nations. In the past 30 years, there has been an increase of 650 million people aged 30-79 who have hypertension. An estimated 46% of adults with hypertension are unaware of their condition because they have not been diagnosed. Therefore, the growing prevalence of hypertension disorders is driving the growth of the ACE inhibitors market.

What Are The Core Segmentation Criteria In The ACE Inhibitors Market?

The ace inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

Which Emerging Trends Are Reshaping The ACE Inhibitors Market Landscape?

Product innovations represent a significant trend gaining momentum within the ACE inhibitors market. Major companies operating in the ACE inhibitors market are dedicated to developing inventive products to solidify their market standing and achieve a competitive advantage. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, announced FDA approval of FILSPARI (sparsentan), which is a pioneering non-immunosuppressive therapy intended for patients with IgA nephropathy (IgAN). Existing treatments for this condition typically involve systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, such as angiotensin-receptor blockers (ARBs). FILSPARI is notable as the sole non-immunosuppressive therapy approved and is a once-daily oral medicine formulated to treat adults with primary IgAN who are at risk of rapid disease development and who commonly present with a UPCR of less than 1.5 g/g and proteinuria.

Which Players Are Shaping The Competitive Landscape Of The ACE InhibitorsXX Market?

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

What Regional Trends Are Shaping Growth In The ACE Inhibitors Market?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

Browse Through More Reports Similar to the Global ACE Inhibitors Market 2025, By The Business Research Company

Synthetic Biology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/synthetic-biology-global-market-report

Digestive Enzyme Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digestive-enzyme-global-market-report

Specialty Enzyme Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/specialty-enzyme-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795